参考文献/References:
[1] Lin X, DeAngelis LM. Treatment of brain metastasis [J]. J
Clin Oncol, 2015, 33(30): 3475-3484.
[2] Prabhu RS, Press RH, Patel KR, et al. Single-fraction ste-
reotactic radiosurgery (SRS) alone versus surgical resection
and SRS for large brain metastases: a multi-institutional
analysis [J]. Int J Radiat Biol Phys, 2017, 99(2): 459-467.
[3] 朱 虹，吕 博，李云海，等. 脑转移瘤放射治疗的预后因
素分析及预后模型的建立[J]. 中国癌症杂志，2014，24
（6）：457-462.
[4] Bennett EE, Angelov L, Vogelbaum MA, et al. The prognos-
tic role of tumor volume in the outcome of patients with
single brain metastasis after stereotactic radiosurgery [J].
World Neurosurg, 2017, 104: 229-238.
[5] Chang WS, Kim HY, Chang JW, et al. Analysis of radiosur-
gical results in patients with brain metastases according to
the number of brain lesions: is stereotactic radiosurgery
effrctive for multiple brain metastases [J]. J Neurosurg,
2010, 113: 73-78.
[6] Siena S, Crinò L, Danova M, et al. Dose-dense temozolo-
mide regimen for the treatment of brain metastases from
melanoma, breast cancer, or lung cancer not amenable to
surgery or radiosurgery: a multicenter phase Ⅱ study [J].
Ann Oncol, 2010, 21: 655-661.
[7] Hardee ME. Combining stereotactic radiosurgery and
systemic therapy for brain metastases: a potential role for
temozolomide [J]. Front Oncol, 2012, 2: 99.
[8] Hashimoto K, Narita Y, Matsusshita Y, et al. Methylation
status of O6-methylguanine-DNA-methyl transferase pro-
moter region in non-small-cell lung cancer patients with
brain metastasis [J]. Clin Transl Oncol, 2012, 14: 31-35.
[9] Wu PF, Kuo KT, Kuo LT, et al. O(6)-Methylguanine-DNA
methyltransferase expression and prognostic value in brain
metastases of lung cancers [J]. Lung Cancer, 2010, 68: 484-
490.
[10] Rades D, Hornung D, Veninga T, et al. Single brain meta-
stasis: radiosurgery alone compared with radiosurgery plus
up-front whole-brain radiotherapy [J]. Cancer, 2012, 118
(11): 2980-2985.
[11] Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosur-
gery alone vs radiosurgery with whole brain radiation
therapy on cognitive function in patients with 1 to 3 brain
metastases: a randomized clinical trial [J]. JAMA, 2016, 316
(4): 401-409.
[12] Deng X, Zheng Z, Lin B, et al. The efficacy and roles of
combining temozolomide with whole brain radiotherapy in
protection neurocognitive function and improvement quality
of life of non-small-cell lung cancer patients with brain
metastases [J]. BMC Cancer, 2017, 17(1): 42.
[13] Liu HP, Zheng KB. Efficacy and safety of temozolomide
plus whole-brain radiotherapy in the treatment of intracra-
nial metastases [J]. J Cancer Res Ther, 2017, 13: 785-789.
[14] Koba T, Kijima T, Takimoto T, et al. Rapid intracranial
response to osimertinib, without radiotherapy, in nonsmall
cell lung cancer patients harboring the EGFR T790M
mutation: two case report [J]. Medicine, 2017, 96: e6087.
[15] Ahluwalia MS, Chao ST, Parsons MW, et al. Phase Ⅱ trial
of sunitinib as adjuvant therapy after stereotactic radiosur-
gery in patients with 1-3 newly diagnosed brain metastases
[J]. J Neurooncol, 2015, 124 (3): 485-491.
[16] Kaidar-Person O, Zagar TM, Deal A, et al. The incidence of
radiation necrosis following stereotactic radiotherapy for
melanoma brain metastases: the potential impact of immu-
notherapy [J]. Anti-cancer Drugs, 2017, 28(6): 669-675.